SUBSCRIBE
SUBSCRIBE

CymaBay Therapeutics

NEWS
Business
Bay Area’s CymaBay Therapeutics CEO To Retire, Interim Leader Named
March 29, 2017
 · 
5 min read
Analysts Not Sold On Medivation’s Xtandi as Breast Cancer Drug
Biotech Beach
With Promising New Gout Treatment In Its Pipeline, 2015 Will Be Big Year For CymaBay Therapeutics
November 13, 2014
 · 
2 min read
Load More
JOBS
IN THE PRESS
Policy
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
March 4, 2024
 · 
5 min read
Business
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
February 28, 2024
 · 
15 min read
Drug Development
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay’s Seladelpar in Primary Biliary Cholangitis
February 21, 2024
 · 
8 min read
Biotech Bay
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 20, 2024
February 20, 2024
 · 
2 min read
Biotech Bay
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
February 12, 2024
 · 
6 min read
Deals
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
February 12, 2024
 · 
11 min read
Biotech Bay
CymaBay Therapeutics to Participate in Upcoming Investment Conferences
January 31, 2024
 · 
1 min read
Biotech Bay
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 16, 2024
January 16, 2024
 · 
2 min read
Drug Development
New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay’s Seladelpar
January 3, 2024
 · 
5 min read
Biotech Bay
CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
January 2, 2024
 · 
1 min read
Load More